PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “BLADDER DISEASES”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 289 records · Page 16Linked to original sources
PubMed1996

Mast cell counts are not useful in the diagnosis of nonulcerative interstitial cystitis.

PURPOSE: Mast cell counts have been advocated as useful in the pathological diagnosis of interstitial cystitis. To determine the clinical significance of mucosal and detrusor muscle mast cells we quantified mast cells within the lamina propria and detrusor muscle in nonulcerative interstitial cystitis, and various inflammatory and neoplastic bladder diseases. MATERIALS AND METHODS: Mast cells from Giemsa stained sections were enumerated from 8 cases of clinically diagnosed nonulcerated interstitial cystitis and 32 control cases having inflammatory or neoplastic bladder disease. Cystectomy specimens from controls also included sections from normal (5) and inflamed transitional mucosa (4) distant from the invasive tumor. RESULTS: There was no significant difference in mast cell counts when considered absolutely or relative to the muscle-to-mucosa ratio in cases of nonulcerative interstitial cystitis and controls. CONCLUSIONS: Our findings indicate that mast cell counts are not useful in the evaluation of nonulcerative interstitial cystitis and do not represent a diagnostic criterion for inclusion or exclusion of the disease.

Adult↗
PubMed1994

Interleukin-1B: a clinically relevant urinary marker.

Urinary cytokines as markers for the intravesical inflammatory response have become an active area of research. Interleukin-1b, a well studied and early produced cytokine in the immune recognition cascade, was evaluated. After extensive analysis of 56 control and study group urine samples, a simplified and reliable protocol for the preparation of urine before cytokine analysis was devised. The application of an available serum interleukin-1b enzyme-linked immunosorbent assay kit for urinary interleukin-1b analysis was then tested. Finally, a reference value for interleukin-1b in normal human urine was established and urinary interleukin-1b was measured in various bladder diseases. The normal and interstitial cystitis groups showed no interleukin-1b elevation. Significant elevation of urinary interleukin-1b was found in patients with bacterial cystitis compared to the interstitial cystitis and control groups (p < 0.001). Of the patients with bladder tumors 58% showed elevation of urinary interleukin-1b (p < 0.001). Urinary interleukin-1b may be used as a marker to distinguish between bacterial and interstitial cystitis. The absence of urinary interleukin-1b in interstitial cystitis argues against an immunological or autoimmune etiology of the disorder. This study represents an important methodological approach to cytokine subtyping of bladder diseases.

Adolescent↗
PubMed1987

The use of CA-50 radioimmunoassay test in diagnosis of urologic malignancy. Tie for second place Jobst award.

Circulating levels of the oncofetal antigen, CA-50, have been used to differentiate benign and malignant disease of the prostate, bladder, and kidney, taking 17 units/ml as the upper limit of normal. All 60 normal subjects and 59 of 61 (97%) patients with benign prostatic hypertrophy had levels below 17 units/ml. The test was positive in 29 of 68 (43%) patients with prostatic carcinoma, including 24 of 34 (75%) with metastases, but only five of 34 (15%) patients without metastases (P less than 0.01). Positivity also correlated with histologic grade: 0 per cent with well-differentiated tumors (n = 8), 33 per cent with moderately differentiated (n = 11), and 66 per cent with poorly differentiated tumors (n = 27). All 14 patients with benign bladder disease had negative values, whereas 13 of 21 (62%) patients with bladder carcinoma had positive. Noninvasive tumors were less likely to give a positive value than invasive tumors (42 vs 89%; P less than 0.05). One of 11 (9%) patients with benign renal conditions was positive as opposed to seven of 15 (47%) patients with renal carcinoma. The overall sensitivity of the CA-50 test for urologic malignancy was 47 per cent and specificity was 97 per cent; moreover, serum levels correlated with stage and grade of disease.

Antigens, Neoplasm↗